Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986224 ascending-dose study in healthy volunteers and chronic heart failure patients
NL-OMON48858Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986224 in heart failure with reduced ejection fraction (HFrEF) (22 arms), sponsored by Bristol Myers Squibb. Started Sep 2017; status: active, not recruiting.
02
Drugs
BMS-986224
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON48858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48858.